See more : Scout Gaming Group AB (publ) (SCTGF) Income Statement Analysis – Financial Results
Complete financial analysis of Cerecor Inc. (CERC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cerecor Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PT Berkah Prima Perkasa Tbk (BLUE.JK) Income Statement Analysis – Financial Results
- Beijing Enterprises Urban Resources Group Limited (3718.HK) Income Statement Analysis – Financial Results
- Befesa S.A. (BFSA.DE) Income Statement Analysis – Financial Results
- HannsTouch Solution Incorporated (3049.TW) Income Statement Analysis – Financial Results
- HNI Corporation (HNI) Income Statement Analysis – Financial Results
Cerecor Inc. (CERC)
About Cerecor Inc.
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
Veracyte Announces Clinical Utility Study Published in CHEST Demonstrates Envisia Genomic Classifier’s Ability to Improve IPF Diagnosis
Sowell Financial Services LLC Buys Shares of 2,166 iShares Commodities Select Strategy ETF (NASDAQ:COMT)
The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates
ACADIA Pharmaceuticals: The Worst-Case Scenario For Investors (NASDAQ:ACAD)
Expect to bring down our debt by 50% this year: Tata Power CMD
The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs
Indian Energy Exchange launches real-time electricity market
Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
Cerecor Announces FDA Clearance of IND for CERC-002 in COVID-19 Induced ARDS
Aluminium Association of India urges CERC to look into markets for renewable energy certificates
Source: https://incomestatements.info
Category: Stock Reports